Article PDF
References
Schroeder, S.A., Gaughan, D.M. & Swift, M. Protection against bronchial asthma by CFTR δF508 mutation: A heterozygote advantage in cystic flbrosis. Nature Med. 1, 703–705 (1995).
Mennie, M., Gilfillan, A. & Brock, D.J.H. Heterozygotes for the δF508 cystic fibrosis allele are not protected against bronchial asthma. Nature Med. 1, 978–979 (1995).
Garenne, M., Ronsmans, C. & Campbell, H. The magnitude of mortality from acute respiratory infections in children under 5 years in developing countries. Wld Hlth Statist. Q. 45, 180–191 (1992).
Gergen, P.J. & Weiss, K.B. Epidemiology of asthma. in Asthma and Rhinitis (eds Busse, W.W. & Holgate, S.T.) (Blackwell Science, Oxford, 1995).
Newman-Taylor, A. Environmental determinants of asthma. Lancet 345, 296–299 (1995).
Romagnani, S. Role of Th2 lymphocytes in the genesis of allergic disorders and mechanisms involved in their development. in Asthma: Physiology, Immunopharmacology and Treatment Fourth International Symposium (Academic Press, 1993).
Jorde, L.B. & Lathrop, G.M. A test of the heterozygote-advantage hypothesis in cystic fibrosis carriers. Am. J. hum. Genet. 42, 808–815 (1988).
Korppi, M. et al. Bronchial asthma and hyperre-activity after early childhood bronchiolitis or pneumonia. An 8-year follow-up study. Arch. Pediatr. Adolesc. Med. 148, 1079–1084 (1194).
Mennie, M.F. et al. Prenatal screening for cystic fibrosis. Lancet 340, 214–217 (1992).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Campbell, H. The cystic fibrosis heterozygote advantage. Nat Med 1, 1100 (1995). https://doi.org/10.1038/nm1195-1100b
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm1195-1100b